Cover Image
Market Research Report
Product code 
987966

Excessive Daytime Sleepiness - Pipeline Insight, 2021

Published: Pre-Order | DelveInsight Business Research LLP | 60 Pages | Delivery time: 2-10 business days

Price

Back to Top
Excessive Daytime Sleepiness - Pipeline Insight, 2021
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 60 Pages
Delivery time: 2-10 business days
  • Description
  • Table of Contents
  • List of Tables

DelveInsight's , "Excessive Daytime Sleepiness - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Excessive Daytime Sleepiness pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Excessive Daytime Sleepiness Understanding

Excessive Daytime Sleepiness: Overview

Excessive daytime sleepiness is not a condition in itself but a symptom of different conditions. Any condition that restrains an individual from getting good sleep at night can cause excessive daytime sleepiness. The common causes for excessive daytime sleepiness include sleep apnea (a potentially serious condition with abnormal breathing pattern during night), RLS (restless leg syndrome), depression, hypersomnia, and narcolepsy. Hypersomnia and narcolepsy have some similar characteristics. Both the condition involves excessive daytime sleepiness but narcolepsy is rare and more severe with sudden and uncontrollable sleeps, often at inconvenient times. People with narcolepsy also have greater nighttime sleep disturbance than those with hypersomnia, resulting in reduced sleep quality.

"Excessive Daytime Sleepiness - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Excessive Daytime Sleepiness pipeline landscape is provided which includes the disease overview and Excessive Daytime Sleepiness treatment guidelines. The assessment part of the report embraces, in depth Excessive Daytime Sleepiness commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Excessive Daytime Sleepiness collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

● The companies and academics are working to assess challenges and seek opportunities that could influence Excessive Daytime Sleepiness R&D. The therapies under development are focused on novel approaches to treat/improve Excessive Daytime Sleepiness.

Excessive Daytime Sleepiness Emerging Drugs Chapters

This segment of the Excessive Daytime Sleepiness report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Excessive Daytime Sleepiness Emerging Drugs

● Pentetrazol: Balance Therapeutics

Balance Therapeutics' lead drug candidate, Pentetrazol is a small molecule in development for the treatment of excessive daytime sleepiness due to narcolepsy. The drug has demonstrated good efficacy in its Phase I clinical trials. The drug is a CNS (central nervous system) convulsant that bind to the picrotoxin site of GABA (A) receptor.

● TAK 925: Takeda Pharmaceuticals

Takeda's "breakthrough" drug TAK 925 is currently being evaluated for the treatment of excessive daytime sleepiness due to hypersomnia as well as narcolepsy. The drug has been designated with orphan drug status for narcolepsy. It is an orexin receptor type-2 agonist which plays an important role in the regulation of sleep and wakefulness.

Further product details are provided in the report:

Excessive Daytime Sleepiness: Therapeutic Assessment

This segment of the report provides insights about the different Excessive Daytime Sleepiness drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in Excessive Daytime Sleepiness

There are approx. 10+ key companies which are developing the therapies for Excessive Daytime Sleepiness. The companies which have their Excessive Daytime Sleepiness drug candidates in the most advanced stage, i.e. phase II include, Balance Therapeutics.

● Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

● Route of Administration

Excessive Daytime Sleepiness pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular

● Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule

● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Excessive Daytime Sleepiness: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Excessive Daytime Sleepiness therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Excessive Daytime Sleepiness drugs.

Excessive Daytime Sleepiness Report Insights

  • Excessive Daytime Sleepiness Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Excessive Daytime Sleepiness Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Excessive Daytime Sleepiness drugs?
  • How many Excessive Daytime Sleepiness drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Excessive Daytime Sleepiness?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Excessive Daytime Sleepiness therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Excessive Daytime Sleepiness and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Balance Therapeutics
  • Takeda Pharmaceuticals
  • Benevolent AI Bio
  • Avadel Pharmaceuticals
  • Axsome Therapeutics

Key Products

  • Pentetrazol
  • TAK 925
  • BEN-2001
  • Sodium oxybate
  • AXS-12
Product Code: DIPI1172

Table of Contents

Introduction

Executive Summary

Excessive Daytime Sleepiness: Overview

● Causes

● Mechanism of Action

● Signs and Symptoms

● Diagnosis

● Disease Management

Pipeline Therapeutics

● Comparative Analysis

Therapeutic Assessment

● Assessment by Product Type

● Assessment by Stage and Product Type

● Assessment by Route of Administration

● Assessment by Stage and Route of Administration

● Assessment by Molecule Type

● Assessment by Stage and Molecule Type

Excessive Daytime Sleepiness - DelveInsight's Analytical Perspective

In-depth Commercial Assessment

● Excessive Daytime Sleepiness companies' collaborations, Licensing, Acquisition -Deal Value Trends

Excessive Daytime Sleepiness Collaboration Deals

● Company-Company Collaborations (Licensing / Partnering) Analysis

● Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

● Comparative Analysis

Pentetrazol: Balance Therapeutics

● Product Description

● Research and Development

● Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

● Comparative Analysis

TAK 925: Takeda Pharmaceuticals

● Product Description

● Research and Development

● Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

● Comparative Analysis

Excessive Daytime Sleepiness Key Companies

Excessive Daytime Sleepiness Key Products

Excessive Daytime Sleepiness- Unmet Needs

Excessive Daytime Sleepiness- Market Drivers and Barriers

Excessive Daytime Sleepiness- Future Perspectives and Conclusion

Excessive Daytime Sleepiness Analyst Views

Excessive Daytime Sleepiness Key Companies

Appendix

List of Tables

  • Table 1 Total Products for Excessive Daytime Sleepiness
  • Table 2 Late Stage Products
  • Table 3 Mid Stage Products
  • Table 4 Early Stage Products
  • Table 5 Pre-clinical & Discovery Stage Products
  • Table 6 Assessment by Product Type
  • Table 7 Assessment by Stage and Product Type
  • Table 8 Assessment by Route of Administration
  • Table 9 Assessment by Stage and Route of Administration
  • Table 10 Assessment by Molecule Type
  • Table 11 Assessment by Stage and Molecule Type
  • Table 12 Inactive Products

List of Figures

  • Figure 1 Total Products for Excessive Daytime Sleepiness
  • Figure 2 Late Stage Products
  • Figure 3 Mid Stage Products
  • Figure 4 Early Stage Products
  • Figure 5 Preclinical and Discovery Stage Products
  • Figure 6 Assessment by Product Type
  • Figure 7 Assessment by Stage and Product Type
  • Figure 8 Assessment by Route of Administration
  • Figure 9 Assessment by Stage and Route of Administration
  • Figure 10 Assessment by Molecule Type
  • Figure 11 Assessment by Stage and Molecule Type
  • Figure 12 Inactive Products